Final Stage 2 Results of the CLL11 Trial
Jennifer Brown, MD, PhD, discusses final stage 2 results of the CLL11 trial at the 2013 American Society of Hematology (ASH) Meeting.
Clinical Pearls
Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses final stage 2 results of the CLL11 trial at the 2013 American Society of Hematology (ASH) Meeting.
- The CLL11 study provided the basis for the approval of GA101 (obinutuzumab)
- GA101 has a different mechanism than rituximab or ofatumumab in that it confers increased direct cell death
- GA101 + chlorambucil compared with chlorambucil alone now has demonstrated a statistically significant improvement in overall survival
- In the direct comparison, GA101 + chlorambucil demonstrated an improvement in progression-free survival compared with rituximab + chlorambucil (27 months vs 16 months)
- GA101 + chlorambucil also has demonstrated a higher complete remission rate and MRD negativity rate
<<<
Recent Videos
Related Content
IPSS-del(5q) Scoring System Enhances Risk Assessment in MDS With 5q Deletions
December 11th 2024Article
At the 2024 ASH Annual Meeting, findings suggested that the IPSS-del(5q) Scoring System may more effectively identify risks in MDS with isolated 5q deletions compared to standard MDS scoring systems.
Read More
